Nora Frey
Investment Manager @ BioScience Managers Limited
Nora Frey is a Series C investor at BioScience Managers Limited focused on Medical and Biopharma. Nora studied modern biology (microbiology, biochemistry) and economics in Basel and holds a masters degree in Microbiology and a PhD in Biochemistry in the field of drug-induced autoimmune diseases from the University of Basel.She was partner at Bellevue Group, Zug, Switzerland and part of the BB Biotech management team managing up to CHF 4B inpublic and private biotech investments. In 2000 she conceived and founded Adamant Biomedical Investments AG in Basel, Switzerland.Among several other awards, Nora was voted finalist in the Ernst &Young Entrepreneur of the Year Award in Switzerland. She was responsible for the establishment of a subsidiary of Adamant, Adamant Ventures Ltd., in Edinburgh, UK.Towards the end of 2008, Nora left Adamant to found Cederberg Advisors.Nora is a citizen of Germany and Switzerland.
- Total investments:
- 2
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries Nora Frey invests in
Stages Nora Frey invests in
Countries Nora Frey invests in
Investment Focus
Industry
- Medical 1 (50%)
- Biopharma 1 (50%)
- Biotechnology 1 (50%)
- Pharmaceutical 1 (50%)
Stage
- Series C 1 (50%)
- Series D 1 (50%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Vertero
|
Axial Therapeutics is a clinical stage biopharmaceutical company harnessing the gut-brain axis to develop novel Central Nervous System (CNS) Therapeutics to improve the quality of life for people with CNS diseases and disorders. | $37.3M / Series C / Oct 13, 2021 | |
|
Vertero
|
Axial Therapeutics is a clinical stage biopharmaceutical company harnessing the gut-brain axis to develop novel Central Nervous System (CNS) Therapeutics to improve the quality of life for people with CNS diseases and disorders. | $20M / Series D |
Co-Investors
About BioScience Managers Limited
BioScience Managers Pty Ltd (formerly IB Managers) is a leading life sciences investment firm, headquartered in Melbourne, Australia. Established in 2003, BioScience Managers offers a global, multi-disciplinary team, bringing an international perspective together with the track record, networks and expertise required to convert that perspectiveinto informed, high return investment decisions.We operate a high value-add model, providing assistance and support to portfolio companies via our global team and international network of independent industry advisors. With combined experience of over 170 investments, more than 40 IPO’s/ reversals in Europe, the USA and Australia, and a diverse skillset specific to the bio-based industries, we aim to provide investee companies with significant value-add over and above capital invested.Alongside our funds management business, Phillip Bioscience Advisory provides specialist corporate advisory services to healthcare and life sciences companies.
BioScience Managers Limited Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Amanda Gillon
Investment Analyst
|
|||
Matt McNamara
Managing Director
|
|||
|
Nora Frey
Investment Manager
|
|||
Bronwyn Dilley
senior executive
|
|||
Jeremy Curnock Cook
Manager
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Nora Frey invest in?
Nora Frey invests primarily in Medical, Biopharma and Biotechnology startups, most often at Series C and Series D stage. Most of the 2 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Nora Frey last invest?
The most recent investment recorded for Nora Frey closed in Oct 2021. Shizune tracks 2 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
